Cosmos Health reported third‑quarter 2025 revenue of $17.11 million, a 38% increase from $12.41 million in the same period last year, and a record gross profit of $2.60 million, up 116% from $1.21 million in Q3 2024. The company’s gross margin expanded to 15.21% from 9.72% year‑over‑year, while the net loss widened to $5.35 million, largely driven by non‑cash charges related to derivatives, convertible notes, and foreign‑currency transactions. Adjusted EBITDA narrowed to a loss of $0.19 million, a 74% improvement over the $0.70 million loss reported in Q3 2024.
Cosmos Health’s core businesses drove the strong results. Contract manufacturing at Cana Laboratories accelerated, adding new high‑margin contracts such as the MYCOFAGYL® pessary agreement with Medical Pharmaquality. Sales through the UK wholesaler Decahedron grew, and the distribution network via CosmoFarm expanded further. Proprietary nutraceutical brands Sky Premium Life and C‑Sept/C‑Scrub contributed to a higher‑margin mix, supporting the record gross margin.
Cash and liquidity improved markedly. Cash and cash equivalents rose to $4.63 million from $0.66 million at the end of the prior quarter. The company also purchased $1 million of Ethereum under its $300 million digital‑asset financing facility, signaling a strategic diversification of its treasury and a stronger working‑capital position.
Over the nine‑month period ended September 30, 2025, Cosmos Health generated $45.57 million in revenue, up 13% from $40.20 million in the prior year, and $5.82 million in gross profit, a 76% increase from $3.31 million in 2024. The net loss for the nine months was $5.35 million, reflecting the same non‑cash charge profile that widened the quarterly loss.
CEO Greg Siokas described the quarter as “defining” for the company, praising the scale of Cana Laboratories’ contract manufacturing and the growth of the CosmoFarm distribution network. He highlighted the inaugural Ethereum purchase as a milestone in the company’s digital‑asset strategy and emphasized confidence in maintaining high‑margin operations. Siokas also noted that the company’s focus on operational efficiency and strategic investments is positioning Cosmos Health for continued growth and a path toward profitability.
The record revenue and gross profit underscore strong demand across Cosmos Health’s segments and operational efficiencies that have expanded margins. The widened net loss is attributable to non‑cash charges rather than a decline in operating performance, and the improved adjusted EBITDA signals progress toward profitability. The strengthened cash position and digital‑asset strategy provide financial flexibility to support future investments in high‑margin contracts and product development. Overall, the results reflect a company that is scaling its core businesses while building a diversified financial foundation for long‑term growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.